Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 3/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.46 |
| ▸ | SRC | P12931 | 9/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | KIF5B | P33176 | 1/20 | 0.45 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24117644 | 0.88 | ENPP1 (0.49) | PDPK1ENPP1SRCEGFRERBB2 | |
| SCHEMBL19645708 | 0.87 | RET (0.42) | SRCEGFRERBB2KDRRET | |
| SCHEMBL19645707 | 0.84 | PDGFRB (0.53) | PDPK1SRCKDM4EEGFRKDR | |
| SCHEMBL6786274 | 0.84 | SRC (0.48) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL2748840 | 0.81 | EGFR (0.48) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL2747384 | 0.81 | SRC (0.46) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL30288418 | 0.81 | EGFR (0.48) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL6781301 | 0.81 | SRC (0.47) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL256577 | 0.81 | PDPK1 (0.47) | PDPK1ENPP1SRCKDM4EALDH1A1 | |
| SCHEMBL31716209 | 0.81 | SRC (0.46) | PDPK1ENPP1SRCKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | EXELIXIS, INC. | 2022-06-23 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ABBVIE INC (US) | 2020-09-17 | — | — | US | disclosed |
| EP-3676254-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | AbbVie Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| CN-111315723-A | Extramembranous nucleotide pyrophosphatase-phosphodiesterase 1(ENPP-1) inhibitor and application thereof | 艾伯维公司 | 2020-06-19 | — | — | CN | disclosed |
| US-20200190032-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | BRISTOL-MYERS SQUIBB COMPANY | 2020-06-18 | — | — | US | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2019046778-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | MAVUPHARMA, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-9969692-B2 | Process for preparing quinoline derivatives | EXELIXIS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200291024-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | PDPK1 332/4885ENPP1 1/4885SRC 2805/4885 |
| US-20230183239-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE-PHOSPHODIESTERASE 1 (ENPP-1) INHIBITORS AND USES THEREOF | ENPP1, ENPP3, STING1 | PDPK1 332/4885ENPP1 1/4885SRC 2805/4885 |
| US-20200190032-A1 | Malate salt of N-(4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | MDH2, MDH1, SLC25A11 | PDPK1 3561/4885ENPP1 3529/4885SRC 1149/4885 |
| US-20220194902-A1 | Method of Preparing Fluorine-18 Labeled Cabozantinib and Its Analogs | FGFR1, FLT1, PDGFRA | PDPK1 110/4885ENPP1 4123/4885SRC 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.